The Predicting Effect of ASXL1 Mutation on BCR-ABL Transcript Types and Responses to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia. mfm [Internet]. 2025 Sep. 12 [cited 2026 Apr. 29];36(8). Available from: https://medicalforummonthly.com/index.php/mfm/article/view/5357